Advertisement
BIO vs TMO
Which Stock Would AI Choose? Bio-Rad Laboratories (BIO) vs. Thermo Fisher Scientific (TMO) Stock Comparison
Key Takeaways
- TMO outperforms BIO year-to-date with 18.94% gains compared to 16.34%, reflecting stronger revenue growth in recent quarters.
- BIO trades at a lower P/E ratio (price-to-earnings ratio) of 9.10 versus TMO's 25.78, but faces higher volatility with a beta around 1.16.
- Recent BIO Q1 earnings missed estimates, leading to a sharp share price decline, while TMO reported robust 6% revenue growth.
- Both operate in life sciences tools, but TMO's larger market cap ($174B vs. $6.8B) provides greater stability and diversification.
- Market sentiment favors TMO amid expansions like a new bioprocess center, contrasting BIO's process chromatography challenges.
Introduction
Bio-Rad Laboratories (BIO) and Thermo Fisher Scientific (TMO) are key players in the life sciences sector, providing essential tools for research, diagnostics, and bioprocessing. This comparison analyzes their recent market performance, financial metrics, and positioning amid healthcare sector dynamics. Investors tracking healthcare equipment stocks or seeking relative value in biotech tools will find insights into momentum, risks, and growth drivers, aiding decisions in a volatile environment focused on innovation and efficiency.
BIO Overview and Recent Performance
Bio-Rad Laboratories (BIO) develops and markets products for life science research and clinical diagnostics, including instruments, reagents, and software for applications like PCR (polymerase chain reaction) and chromatography. In recent market activity, shares traded around $253, down sharply following Q1 2026 earnings that reported $592.1 million in revenue and EPS of $1.89, missing analyst estimates amid softer demand in process chromatography. Year-to-date gains stand at 16.34%, with a 52-week range of $211-$343. Sentiment has softened due to earnings shortfalls and analyst price target cuts, though low P/E valuation offers potential appeal for value-oriented traders.
TMO Overview and Recent Performance
Thermo Fisher Scientific (TMO) is a leading provider of analytical instruments, reagents, consumables, software, and services for pharmaceutical, biotechnology, and diagnostics markets. Recent weeks saw shares around $469, with Q1 2026 revenue rising 6% to $11.01 billion and GAAP EPS up 11% to $4.43. Key developments include opening a U.S. bioprocess design center and agreeing to sell its microbiology business for $1 billion. YTD performance reached 18.94%, within a 52-week range of $385-$644, supported by steady growth and a modest dividend yield. Positive catalysts have bolstered sentiment despite broader sector pressures.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases 25 top-performing bots curated by AI from over 351 available, each trading thousands of tickers with diverse styles like short-term scalping (5-60 minutes) or longer holds. Standouts include bots with returns up to 164%, win rates of 50-88%, profit factors of 1.5-7.0, and profit/drawdown ratios exceeding 16, often focusing on semis, AI infrastructure, and industrials amid volatility. These bots adapt strategies dynamically, with max drawdowns ranging $3K-$48K on simulated portfolios. Traders can explore performance stats, backtests, and live signals to match risk profiles—visit the page for real-time rankings and copy-trading options.
Head-to-Head Comparison
Both BIO and TMO serve life sciences but differ in scale: TMO’s diversified segments (instruments, biopharma services) drive consistent growth, while BIO focuses narrower on research tools with higher exposure to R&D spending cycles. Recent momentum shows TMO leading YTD, buoyed by expansions, versus BIO’s post-earnings pullback. Risk factors include BIO’s elevated beta for volatility and TMO’s premium valuation. Sector tailwinds like bioprocessing favor TMO, but BIO’s cheaper multiples highlight value trade-offs in healthcare equipment positioning.
Tickeron AI Verdict
Tickeron’s AI currently leans toward TMO due to superior trend consistency, revenue momentum, lower relative volatility (beta 0.97), and catalysts like bioprocess investments. While BIO offers valuation upside, its recent earnings volatility tempers short-term favorability. Probabilistic edge favors TMO for stability in current conditions.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BIO is a Hold and TMO is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BIO’s FA Score shows that 1 FA rating(s) are green whileTMO’s FA Score has 1 green FA rating(s).
- BIO’s FA Score: 1 green, 4 red.
- TMO’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BIO’s TA Score shows that 3 TA indicator(s) are bullish while TMO’s TA Score has 2 bullish TA indicator(s).
- BIO’s TA Score: 3 bullish, 7 bearish.
- TMO’s TA Score: 2 bullish, 8 bearish.
Price Growth
BIO (@Medical/Nursing Services) experienced а -2.82% price change this week, while TMO (@Medical Specialties) price change was -2.05% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -0.22%. For the same industry, the average monthly price growth was -3.84%, and the average quarterly price growth was -16.30%.
The average weekly price growth across all stocks in the @Medical Specialties industry was +0.45%. For the same industry, the average monthly price growth was +2.48%, and the average quarterly price growth was -3.19%.
Reported Earning Dates
BIO is expected to report earnings on Jul 30, 2026.
TMO is expected to report earnings on Jul 29, 2026.
Industries' Descriptions
@Medical/Nursing Services (-0.22% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
@Medical Specialties (+0.45% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| BIO | TMO | BIO / TMO | |
| Capitalization | 7.64B | 172B | 4% |
| EBITDA | 440M | 11.7B | 4% |
| Gain YTD | -7.221 | -19.763 | 37% |
| P/E Ratio | 46.77 | 25.51 | 183% |
| Revenue | 2.59B | 45.2B | 6% |
| Total Cash | 1.57B | 1.12B | 140% |
| Total Debt | 1.38B | 43.2B | 3% |
BIO | TMO | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 74 | 71 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 83 Overvalued | 13 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 97 | |
SMR RATING 1..100 | 90 | 62 | |
PRICE GROWTH RATING 1..100 | 52 | 55 | |
P/E GROWTH RATING 1..100 | 13 | 43 | |
SEASONALITY SCORE 1..100 | 90 | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
TMO's Valuation (13) in the Medical Specialties industry is significantly better than the same rating for BIO (83). This means that TMO’s stock grew significantly faster than BIO’s over the last 12 months.
TMO's Profit vs Risk Rating (97) in the Medical Specialties industry is in the same range as BIO (100). This means that TMO’s stock grew similarly to BIO’s over the last 12 months.
TMO's SMR Rating (62) in the Medical Specialties industry is in the same range as BIO (90). This means that TMO’s stock grew similarly to BIO’s over the last 12 months.
BIO's Price Growth Rating (52) in the Medical Specialties industry is in the same range as TMO (55). This means that BIO’s stock grew similarly to TMO’s over the last 12 months.
BIO's P/E Growth Rating (13) in the Medical Specialties industry is in the same range as TMO (43). This means that BIO’s stock grew similarly to TMO’s over the last 12 months.
| BIO | TMO | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 70% | 2 days ago 47% |
| Stochastic ODDS (%) | 2 days ago 70% | 2 days ago 62% |
| Momentum ODDS (%) | 2 days ago 69% | 2 days ago 53% |
| MACD ODDS (%) | 2 days ago 74% | 2 days ago 51% |
| TrendWeek ODDS (%) | 2 days ago 66% | 2 days ago 61% |
| TrendMonth ODDS (%) | 2 days ago 67% | 2 days ago 61% |
| Advances ODDS (%) | 8 days ago 66% | 23 days ago 62% |
| Declines ODDS (%) | 2 days ago 68% | 12 days ago 63% |
| BollingerBands ODDS (%) | 2 days ago 71% | 2 days ago 60% |
| Aroon ODDS (%) | 2 days ago 75% | 2 days ago 56% |
Advertisement
BIO and
Correlation & Price change
A.I.dvisor indicates that over the last year, BIO has been closely correlated with A. These tickers have moved in lockstep 68% of the time. This A.I.-generated data suggests there is a high statistical probability that if BIO jumps, then A could also see price increases.
TMO and
Correlation & Price change
A.I.dvisor indicates that over the last year, TMO has been closely correlated with A. These tickers have moved in lockstep 80% of the time. This A.I.-generated data suggests there is a high statistical probability that if TMO jumps, then A could also see price increases.